FOLH1 and neoplasm: PSMA-targeted RLT agents bind to PSMA, a transmembrane glycoprotein highly expressed on prostate cancer cells and, to a lesser extent, on endothelial cells within the neovasculature of several other tumour types, including hepatocellular carcinoma, renal cancer, thyroid cancer, and glioblastoma [29].